Stock CALTX CALLIDITAS THERAPEUTICS AB
Add to a list
To use this feature you must be a member
Log inSign up

Financials Calliditas Therapeutics AB

Equities

CALTX

SE0010441584

Pharmaceuticals

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:52 2024-04-26 am EDT 		5-day change 1st Jan Change
103.7 SEK -0.38% Intraday chart for Calliditas Therapeutics AB +3.18% -18.41%
Apr. 25 European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Thursday Trading MT
Apr. 24 Calliditas Therapeutics Says OLE Study Shows Treatment Response Consistent With Late-Stage NefIgArd Study's Findings MT

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 1,549 2,930 6,972 5,904 5,507 5,566 5,566 -
Enterprise Value (EV) 1 902.7 2,177 5,976 5,162 4,971 6,815 5,441 4,373
P/E ratio -11.7 x -86 x -14.5 x -11.5 x -11.9 x -14.6 x 24.5 x 4.52 x
Yield - - - - - - - -
Capitalization / Revenue - 15.9 x 7,977 x 25.7 x 6.86 x 5.65 x 2.88 x 1.69 x
EV / Revenue - 11.8 x 6,837 x 22.5 x 6.19 x 5.65 x 2.81 x 1.33 x
EV / EBITDA -6.82 x -77.8 x -15.7 x -9.84 x -11.8 x -18.3 x 23.2 x 2.9 x
EV / FCF -7.04 x -24.4 x -12.4 x -11.2 x -15.8 x -9.92 x 23 x 3.27 x
FCF Yield -14.2% -4.09% -8.06% -8.94% -6.31% -10.1% 4.35% 30.6%
Price to Book 2.51 x 3.72 x 5.18 x 5.86 x 6.48 x 20.4 x 17.9 x 5.81 x
Nbr of stocks (in thousands) 35,202 38,708 49,942 52,342 59,573 53,672 53,672 -
Reference price 2 44.00 75.70 139.6 112.8 92.45 103.7 103.7 103.7
Announcement Date 2/7/19 2/14/20 2/18/21 2/24/22 2/23/23 2/21/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net sales 1 - 184.8 0.874 229.3 802.9 1,207 1,935 3,295
EBITDA 1 -132.4 -27.98 -379.7 -524.5 -421.9 -373.1 234.2 1,508
EBIT 1 -132.5 -28.02 -379.7 -524.5 -421.9 -373.1 178.7 1,294
Operating Margin - -15.16% -43,446.22% -228.67% -52.55% -30.91% 9.23% 39.27%
Earnings before Tax (EBT) 1 -132 -32.5 -436.2 -513.4 -409.4 -457 101.5 1,256
Net income 1 -132 -32.58 -433.5 -500.3 -412.3 -466.2 85.39 1,090
Net margin - -17.63% -49,598.86% -218.14% -51.35% -38.63% 4.41% 33.08%
EPS 2 -3.750 -0.8800 -9.660 -9.840 -7.780 -8.690 4.235 22.93
Free Cash Flow 1 -128.2 -89.08 -481.8 -461.6 -313.9 -544.4 236.6 1,337
FCF margin - -48.2% -55,124.49% -201.26% -39.09% -48.16% 12.23% 40.56%
FCF Conversion (EBITDA) - - - - - - 101.03% 88.64%
FCF Conversion (Net income) - - - - - - 277.14% 122.62%
Dividend per Share 2 - - - - - - - -
Announcement Date 2/7/19 2/14/20 2/18/21 2/24/22 2/23/23 2/21/24 - -
1SEK in Million2SEK
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - 198.2 31.2 49.73 64 260.1 429 191.4 269.4 294.6 451.6 383.1 434.5 515.8 622.2
EBITDA 1 -159.4 7.856 -222.1 -208.4 -209.8 -36.23 32.5 -180.1 -75.17 -159.6 41.76 -59.9 -1.933 69.87 185.9
EBIT 1 -159.4 7.856 -222.1 -208.4 -209.8 -36.23 32.5 -180.1 -75.17 -159.6 41.76 -31.64 -1.908 51.69 151.4
Operating Margin - 3.96% -711.86% -418.96% -327.88% -13.93% 7.57% -94.11% -27.91% -54.17% 9.25% -8.26% -0.44% 10.02% 24.33%
Earnings before Tax (EBT) 1 -165.2 6.48 -218.5 -211.4 -192.1 -15.96 10.07 -208 -70.66 -164.1 -14.26 -45.62 -31.65 -1.639 59.07
Net income 1 -159.8 10.84 -219.2 -207 -192.4 -9.111 -3.681 -187.5 -91.93 -168.4 -18.37 -47.16 -33.45 -3.454 57.2
Net margin - 5.47% -702.47% -416.31% -300.67% -3.5% -0.86% -98% -34.13% -57.15% -4.07% -12.31% -7.7% -0.67% 9.19%
EPS 2 -3.200 - - - -3.620 -0.1700 -0.0700 -3.490 -1.710 -3.140 -0.3400 -1.059 -0.0782 1.224 3.481
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 8/19/21 11/18/21 2/24/22 5/18/22 8/18/22 11/14/22 2/23/23 5/16/23 8/17/23 11/7/23 2/21/24 - - - -
1SEK in Million2SEK
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023 2024 2025
Net Debt 1 - - - - - - - -
Net Cash position 1 646 754 996 742 536 7.14 125 1,193
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -128 -89.1 -482 -462 -314 -544 237 1,337
ROE (net income / shareholders' equity) -40.5% -4.63% -43.4% -45.1% -46.5% -84.7% 21.8% 111%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 17.60 20.40 27.00 19.30 14.30 6.240 5.780 17.80
Cash Flow per Share - - - - - - - -
Capex 1 - 18.1 173 - 2.51 3 31 26.6
Capex / Sales - 9.78% 19,749.08% - 0.31% 0.27% 1.6% 0.81%
Announcement Date 2/7/19 2/14/20 2/18/21 2/24/22 2/23/23 2/21/24 - -
1SEK in Million2SEK
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Calliditas Therapeutics AB

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
103.7 SEK
Average target price
208 SEK
Spread / Average Target
+100.58%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
CALLIDITAS THERAPEUTICS AB Stock Calliditas Therapeutics AB
-18.41% 508M
MERCK KGAA Stock Merck KGaA
+5.31% 70.44B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+10.97% 8.94B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-16.83% 4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+43.48% 4.5B
YUHAN CORPORATION Stock Yuhan Corporation
+3.20% 3.85B
INDIVIOR PLC Stock Indivior PLC
+18.82% 2.38B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-21.36% 2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-29.67% 2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+8.38% 1.96B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. CALTX Stock
  4. Financials Calliditas Therapeutics AB